Shots:

• The P-I/II (LEGEND) dose-escalation trial evaluated safety and tolerability, PK, PD & efficacy of EG-70 in patients with BCG-unresponsive high-grade NMIBC with CIS
• The results showed that 83% of patients achieved CR @3mos., no DLTs or SAEs were observed, AEs were limited to transient Grade 1 & 2. The therapy was safe & well-tolerated with promising clinical efficacy in high-grade NMIBC patients with CIS in whom BCG has failed
• EG-70 is a non-viral gene therapy encoding 2 RIG-I agonists that stimulate the innate immune system & IL-12 stimulates the adaptive immune system. The therapy showed the tumor regression in preclinical models of bladder cancer

Ref: PR Newswire | Image: Businesswire